Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma

Figure 1 Viability curves of cholangiocarcinoma cell lines (RBE, HuCC-T1) for 10 chemotherapeutic drugs. A: Idarubicin; B: Epirubicin; C: Doxorubicin; D: Gemcitabine; E: 5-fluorouracil; F: Raltitrexed; G: Oxaliplatin; H: Lobaplatin; I: Cisplatin; J: Irinotecan. 5-FU: 5-fluorouracil.

Figure 2 Cytotoxicity indices of two cholangiocarcinoma cell lines. A: RBE cell line; B: HuCC-T1 cell line. CyI50: Cytotoxicity index; 5-FU: 5-fluorouracil.

Figure 3 Effect of different treatment groups on tumor volume in tumor-bearing mice. A: Bar graph showing tumor growth over 15 days; B: Images of excised tumors from mice in different treatment groups. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. ^dP < 0.0001. IDA: Idarubicin; GP: Gemcitabine and cisplatin.

Figure 4 Flowchart of the clinical study part. IDA: Idarubicin; GemCis: Gemcitabine and cisplatin; TACE: Transarterial chemoembolization.

Figure 5 Kaplan-Meier curves. A: Overall survival; B: Progression-free survival. IDA: Idarubicin; GemCis: Gemcitabine and cisplatin; TACE: Transarterial chemoembolization; OS: Overall survival; PFS: Progression-free survival.